AAA March 2018 – Page 18

Cancer Rop helps inject $12.5m in Oxford Vacmedix

UK-based oncology technology developer Oxford Vacmedix (OVM) closed a £9m ($12.5m) series A round today featuring molecular diagnostics technology producer Cancer Rop and unnamed existing shareholders based in China. Founded in 2012, Oxford Vacmedix has created a platform to develop cancer vaccines and diagnostic tools by exploiting recombinant overlapping peptides (ROP), which stimulate T cell… Continue reading Cancer Rop helps inject $12.5m in Oxford Vacmedix